


[Home](#)
[Learn More](#)
[Logout](#)

 TICKER: [Go](#) COMPANY NAME: [Go](#)

Jazz Pharmaceuticals, Inc. (JAZZ)

OPS/FPS/EPS Charts		
4 Quarters	20 Quarters	5 Years

OC/FC/EBITDA Charts		
20 Quarters	5 Years	Growth Rates

Company	
Profile	News

OPS Ranking Upgrade for Jazz Pharmaceuticals

05/14/2010

Sarasota, FL, May 14, 2010-Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) reported positive OPS (Operational-cashflow Per Share) for its quarter ended March 31, 2010 and StockDiagnostics.com has upgraded its OPS Ranking to "6" from its previous OPS Ranking of "7". Its OPS Ranking has been upgraded for the second consecutive quarter. Jazz Pharmaceuticals' OPS Ranking of "6" is its highest over its previous two years.

The OPS Ranking™ upgrade was based on Jazz Pharmaceuticals' recently filed Cash Flow Statements for its quarter ended March 31, 2010. The company's computed OPS™ (Operational-cashflow Per Share) for the quarter was \$0.19 per share as compared to \$-0.18 per share for the comparable year earlier quarter. OPS for the most recent 12 months ended March 31, 2010 was \$-0.13 per share as compared to \$-3.61 per share for the 12 months ended March 31, 2009. OPS for Jazz Pharmaceuticals' trailing twelve months reached a two year high.

The shares of Jazz Pharmaceuticals were recently trading at \$8.56.

StockDiagnostics.com has issued 1127 OPS Ranking upgrades for 2010. This compares with 1065 OPS Ranking upgrades in the same period last year. For all of 2009, there were 3473 OPS Ranking upgrades.

About OPS Rankings™ changes -- OPS Ranking upgrades and downgrades may predict changes in the momentum of a company's stock price and its inherent or presumed financial health. All OPS Ranking downgrades, even a downgrade from the highest OPS Ranking of "1" to the second highest OPS Ranking of "2" should be treated with equal caution. Similarly, all OPS Ranking upgrades should be considered as equally positive. Even an upgrade from the lowest OPS Ranking of "8" to the second lowest OPS Ranking of "7" can be treated with guarded optimism.

"OPS Rankings" originated from the results of an in-depth 1990-2001, research study on Operational Cashflow that was done by StockDiagnostics.com. The study included 3,885 public companies, whose shares traded at a minimum of \$6.00 per

Top News Stories

08/19/2010

[Twelve Months EBITDA Turns Positive for Jazz Pharmaceuticals](#)

08/18/2010

[Jazz Pharmaceuticals bucks its Industry's Revenue Decline of 1.28% with an Increase of 49.7%](#)

08/17/2010

[Cash Flow from Operations Turns Positive for Jazz Pharmaceuticals' Second Quarter](#)

08/17/2010

[Jazz Pharmaceuticals' Free Cash Flow Turns Positive for its Second Quarter](#)

08/17/2010

[OPS Ranking for Jazz Pharmaceuticals Upgraded by StockDiagnostics.com](#)

05/18/2010

[Jazz Pharmaceuticals' EBITDA Turns Positive for its Twelve Months](#)

05/17/2010

[Jazz Pharmaceuticals bucks its Industry's Revenue Decline of -1.99% with an Increase of 88.84%](#)

05/14/2010

[Jazz Pharmaceuticals' Cash Flow from Operations Turns Positive for its First Quarter](#)

05/14/2010

[First Quarter Free Cash Flow Turns Positive for Jazz Pharmaceuticals](#)

05/14/2010

OPS Ranking Upgrade for Jazz Pharmaceuticals

03/19/2010

share in 1999 and also filed their four quarterly reports for fiscal 1999. The findings revealed that each of the company's "OPS" logically fell into one of eight distinctive risk categories. The categories were the genesis of StockDiagnostics.com's numerical eight point, 1 through 8, OPS rankings.

The ranking of 6, which the company received means that Jazz Pharmaceuticals based on its OPS over its most recent four quarters and its aggregated OPS over its latest twelve months is in the third highest risk category. The results from the study indicated that 46.46% of all the companies in this risk category (an OPS Ranking of 6), which had shares that traded at \$6.00 or above in 1999 had share prices, which failed to get back to the \$6.00 price during 2001.

Statistical research on the other OPS Rankings is available at www.StockDiagnostics.com and is also available at StockTrendNews.com. Additional information on StockDiagnostics, its OPS Rankings and on OPS, including three minute web tutorials, "What is OPS?" and "What are OPS Ratings?", are available at www.StockDiagnostics.com.

About StockDiagnostics.com -- StockDiagnostics.com covers approximately 10,000 publicly traded companies and 216 industries. It provides current and archived OPS Rankings and its proprietary OPS 4 Quarter, 20 Quarter and 5 Year charts on each company and each industry four times per year. Statistical research on the other OPS Rankings is available at www.StockDiagnostics.com and is also available at StockTrendNews.com. StockDiagnostics.com also provides 20 Quarter and 5 Year extended data table "Free Cash Pro" charts which track EBITDA, Free Cash Flow and Cash Flow From Operations (CFFO). These charts are primarily used by analysts and professional investors.

StockDiagnostics.com has access to a proprietary data refinery that automates the process of collecting, sorting and organizing large amounts of securities pricing and financial data into comparative financial ratios. These ratios are used to identify Financial Statement anomalies and securities pricing variances to monitor changes in the performance of public companies. Go to www.StockDiagnostics.com for a description of StockDiagnostics.com's patent-pending technical applications, such as OPS, OPS Rankings, The EPS Syndrome and more. Three minute videos on OPS and OPS rankings are available at www.StockDiagnostics.com.

Copyright 2010 StockTrendNews.com

[EBITDA Turns Positive for Jazz Pharmaceuticals' Twelve Months](#)

03/18/2010

[Latest 3 months Revenue for Jazz Pharmaceuticals is Up 95.38% according to T12-NEWS](#)

03/17/2010

[Fourth Quarter Cash Flow from Operations Turns Positive for Jazz Pharmaceuticals](#)

03/17/2010

[Fourth Quarter Free Cash Flow Turns Positive for Jazz Pharmaceuticals](#)

03/17/2010

[StockDiagnostics.com Upgrades Jazz Pharmaceuticals' OPS Ranking](#)

11/13/2009

[Jazz Pharmaceuticals' EBITDA Turns Positive for its Third Quarter](#)

11/11/2009

[Cash Flow from Operations for Jazz Pharmaceuticals Reaches Two Year High](#)

11/11/2009

[Jazz Pharmaceuticals' Free Cash Flow Hits Two Year High](#)

11/11/2009

[Jazz Pharmaceuticals' OPS Ranking of "8" Reiterated by StockDiagnostics.com](#)

11/11/2009

[Latest 12 months Revenue for Jazz Pharmaceuticals is Up 73.13% according to T12-NEWS](#)

08/20/2009

[Jazz Pharmaceuticals' EBITDA Turns Positive for its Second Quarter](#)

08/19/2009

[T12-NEWS reports that the Jazz Pharmaceuticals' Revenue for its 12 month ended June 30, 2009 Increased by 44.06%](#)

08/18/2009

[Jazz Pharmaceuticals' Cash Flow from Operations Hits Two Year High](#)

08/18/2009

[Free Cash Flow for Jazz Pharmaceuticals Reaches Two Year High](#)

08/18/2009

[StockDiagnostics.com Has Issued a Cashless Earnings Warning For Jazz Pharmaceuticals](#)

08/18/2009

[OPS Ranking of "8" Reiteration for Jazz Pharmaceuticals](#)

08/18/2009

[Free Cash Flow for Jazz Pharmaceuticals Reaches Two Year High](#)

05/14/2009

[Two Year High in EBITDA for Jazz Pharmaceuticals](#)

05/12/2009

[Jazz Pharmaceuticals' OPS Ranking of "8" Reiterated by StockDiagnostics.com](#)

05/12/2009

[Two Year High in Free Cash Flow for Jazz Pharmaceuticals](#)

05/12/2009

[Cash Flow from Operations for Jazz Pharmaceuticals Reaches Two Year High](#)

03/31/2009

[EBITDA Improves 14.6% for Jazz Pharmaceuticals](#)

03/30/2009

[StockDiagnostics.com Reiterates Jazz Pharmaceuticals' OPS Ranking of "8"](#)

03/30/2009

[Free Cash Flow Improves 35% for Jazz Pharmaceuticals](#)

03/30/2009

[Cash Flow from Operations for Jazz Pharmaceuticals Improves 33%](#)

11/20/2008

[EBITDA for Jazz Pharmaceuticals Deteriorates 36%](#)

11/19/2008

[Jazz Pharmaceuticals' OPS Ranking of "8"](#)